|
Readers react to the economic turmoil of the past year and look longingly forward to 2012.
Dec 2, 2011
By:
Rich Whitworth, Amy Ritter
Readers react to the economic turmoil of the past year and look longingly forward to 2012.
|
Dec 1, 2011
By:
Amy Ritter
The justice department announced that Merck has agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx.
|
Nov 23, 2011
By:
Amy Ritter
On Nov. 17, 2011, a bill that would increase penalties for those convicted of trafficking in counterfeit drugs was introduced in the House of Representatives. The Counterfeit Drug Penalty Enhancement Act of 2011, cosponsored by four US Senators and two US Representatives.
|
Nov 17, 2011
By:
Amy Ritter
AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the World Health Organization agreed to share information on tuberculosis compounds within their respective drug pipelines, according to the Critical Path to TB Drug Regimens. The purpose of the agreement is to promote information sharing around scientific and clinical studies so that partners can identify opportunities to test compounds in combination.
|
Nov 3, 2011
By:
Amy Ritter
In response to the increase in drug shortages over the past three years, President Obama issued an executive order on Oct. 31, 2011 that directs FDA to take several steps to prevent and reduce drug shortages.
|
Oct 27, 2011
By:
Amy Ritter
Merck, Sharpe, and Dohme (MSD) and Singapore's Economic Development Board jointly announced plans for significant investments by MSD to improve its existing manufacturing facilities in Singapore, as well as for new manufacturing, marketing, and research activities.
|
Oct 20, 2011
By:
Amy Ritter
At the request of the US Senate Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, the Government Accountability Office conducted an investigation into doctor shopping in Medicare Part D.
|
Oct 13, 2011
By:
Amy Ritter
In response to concerns about the sustainability of US drug-development efforts, FDA has released a report that outlines several steps that FDA will take to spur biomedical innovation and ensure that such innovation can be quickly translated into safe and effective therapies.
|
Oct 6, 2011
By:
Amy Ritter
The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction.
|
|
